• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 10600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022

Biopharmaceutical Projects

Project Indication Therapeutic Area Laboratory Preclinical Development Phase I Phase II Phase III
CIGB 300: Proapoptotic peptide that acts on phosphorylation mediated by CK2 Cervical Cancer Oncology
Heberprot-P: Recombinant human epidermal growth factor, for scarring Diabetic foot ulcer Diabetes and scarring
Nasvac vaccine: Therapeutic recombinant vaccine Chronic hepatitis B virus infection Viral diseases
CIGB 845: Neuroprotective agent Neuroprotection Neurology
Heberprovac: Prostate Cancer Vaccine Prostate cancer Oncology
Heberferon: Pharmaceutical formulation for parenteral use containing IFN alpha2b and gamma. Antiviral action. COVID-19 Viral diseases
Nasalferon: Nasal pharmaceutical solution, containing recombinant human interferon alpha 2b Prophylaxis of SARS-CoV-2 virus infection Viral diseases
Heberferon: Pharmaceutical formulation for parenteral use containing IFN alfa2b and gamma. Anti-tumor action Basal cell carcinoma Oncology
CIGB 247: Active Immunotherapy for Cancer Treatment Ovarian cancer Oncology
CIGB 814: Deadly type of modified peptic ligament Rheumatoid arthritis Autoimmune diseases
CIGB 500: Cytoprotective agent of cardiac tissue Reduce the extent of myocardial infarction and protect the epithelial organs of the body from damage caused by ischemia-reperfusion events Cardiology
CIGB 247: Active Immunotherapy for Cancer Treatment Hepatocarcinoma Oncología
CIGB 2020: Therapy for the activation of multiple receptors of the innate immune system Innate immune response Viral diseases
CR3 AIDS vaccine Aids Viral diseases
CIGB 552: Anti-tumor peptide targeting molecular targets Cancer Oncology
CIGB 325: Proapoptotic peptide that acts on phosphorylation mediated by CK2 COVID-19 Viral diseases
CIGB 300: Proapoptotic peptide that acts on phosphorylation mediated by CK2 Lung cancer Oncology
CIGB 300: Proapoptotic peptide that acts on phosphorylation mediated by CK2 Leukemia Oncology
CIGB 470: Active Immunotherapy for Age-Related Macular Degeneration. Age-related macular degeneration (AMD) Oftalmology
CIGB 210: Therapy for COVID-19 COVID-19 Infectious diseases
Tir 8: IL-1 inhibitor Cancer, rheumatoid arthritis Oncology, Autoimmune Diseases
HCV Vaccine: Hepatitis C virus preventive vaccine Hepatitis C virus Viral diseases
CIGB 166: Anti-VEGF antibody Age-related macular degeneration (AMD) Oftalmology
FCB stroke ring Ictus Neurology
CIGB 210: Anti-HIV therapy HIV Infectious diseases
IFN Beta-Ring FCB (EM) Multiple sclerosis Neurology
CIGB 50: IL-15 AR vaccine Rheumatoid arthritis autoimmune diseases
CIGB 540: Antifibrotic peptide Keloids and hypertrophic scars Dermatology
CIGB 55: IL-15 Antagonist Peptide Rheumatoid arthritis Autoimmune diseases
Acellular Pertussis Vaccine Whooping cough Infectious diseases
CIGB 428: Treatment for Diabetic Neuropathy Diabetic Neuropathy Neurology
Jusvinza (CIGB 258): Therapy for COVID-19 COVID-19 Viral diseases
CIGB 530: Hepatic cytoprotective agent Liver fibrosis gastroenterology
Antivirals against dengue Dengue Viral diseases
Dengue vaccine Dengue Viral diseases